A cumulative score based on preoperative fibrinogen and the neutrophil–lymphocyte ratio to predict outcomes in resectable gastric cancer
Authors Liu X, Liu Z, Lin E, Chen Y, Sun X, Zhou Z
Received 19 May 2018
Accepted for publication 22 June 2018
Published 28 August 2018 Volume 2018:10 Pages 3007—3014
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 4
Editor who approved publication: Dr Antonella D'Anneo
Xuechao Liu,1,2,* Zhimin Liu,1,2,* Enzi Lin,3,* Yingbo Chen,1,2 Xiaowei Sun,1,2 Zhiwei Zhou1,2
1Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China; 2Department of Gastric Surgery, Sun Yat-sen University Cancer Center, 510060, Guangzhou, People’s Republic of China; 3Surgical Oncology Session No.1, Cancer Hospital of Shantou University Medical College, Shantou, 515041, People’s Republic of China
*These authors contributed equally to this work
Background: Recent studies have revealed that preoperative fibrinogen and the neutrophil–lymphocyte ratio (NLR) are associated with poor outcome in gastric cancer (GC). We aimed to evaluate whether the fibrinogen and the NLR score had a consistent prognostic value for resectable GC.
Methods: We analyzed 1,293 consecutive patients who underwent curative surgery for GC. The F-NLR score was 2 for patients with hyperfibrinogenemia (>400 mg/dL) and elevated NLR (≥5.0), 1 for those with one abnormal index, and 0 for those with no abnormal indices.
Results: We found that higher F-NLR scores were associated with larger tumor size, deeper tumor invasion and more lymph node metastasis (all P<0.05). In a multivariate analysis, F-NLR independently predicted postoperative survival (P<0.001). When stratified by tumor–node–metastasis (TNM) stage, the prognostic value of F-NLR was still maintained for stages I–II (P<0.001) and stage III (P=0.003). Of note, F-NLR also effectively stratified overall survival (OS) irrespective of age, adjuvant chemotherapy administration, tumor location and histological grade (all P<0.05). Furthermore, F-NLR and TNM stratified 5-year OS from 61% (F-NLR 0) to 15% (F-NLR 2) and from 92% (stage I) to 37% (stage III), respectively. Utilizing both F-NLR and TNM, 5-year OS ranged from 93% (F-NLR 0, TNM I) to 6% (F-NLR 2, TNM III).
Conclusion: The F-NLR score independently predicts outcomes in GC patients after curative surgery. Therefore, it should be implemented in routine clinical practice for identifying more high-risk patients.
Keywords: F-NLR score, gastric cancer, prognosis, adjuvant chemotherapy, curative surgery
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]